Trials / Unknown
UnknownNCT04056975
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- EVIVE Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Detailed description
Protocol Number: SP071744 Study Stage: Phase I Study Number: 1 site Subject Number: up to 54 patients with Relapsed or Refractory B-cell Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Anti-CD19m-CD3 Antibody Injection | Intravenous Infusion |
Timeline
- Start date
- 2019-09-15
- Primary completion
- 2021-09-30
- Completion
- 2022-01-27
- First posted
- 2019-08-14
- Last updated
- 2019-08-14
Source: ClinicalTrials.gov record NCT04056975. Inclusion in this directory is not an endorsement.